Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Employees

467

Sector

Biotechnology & Medical Research

Calendar

2024-10-30 - Q3 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-09-06	4.005 $	-9.80%	1,175,528
24-09-05	4.440 $	+8.29%	871,280
24-09-04	4.100 $	+6.49%	527,618
24-09-03	3.850 $	-2.04%	630,136
24-08-30	3.930 $	+3.15%	347,889

Delayed Quote Nasdaq, September 06, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.005USD

Average target price

10.22USD

Spread / Average Target

+155.24%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-06 pm EDT			5-day change	1st Jan Change
4.005 ^USD	-9.80%		+1.91%	-37.81%

Sep. 06	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower	MT
Sep. 04	European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	MT

Capitalization	1.07B	P/E ratio 2024 *	-4.8x	P/E ratio 2025 *	-5.63x
Enterprise value	415M	EV / Sales 2024 *	27.2x	EV / Sales 2025 *	9.18x
Free-Float	3.32%	Yield 2024 *	-	Yield 2025 *	-

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower	Sep. 06	MT
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	Sep. 04	MT
Oxford Biomedica plc Appoints Lucinda Crabtree as Board Member	Sep. 03	CI
Oxford Biomedica plc Appoints Lucinda Crabtree as Chief Financial Officer	Sep. 03	CI
European Equities Traded in the US as American Depositary Receipts Edge Lower Friday; Set to End Week Up 0.5%	Aug. 30	MT
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Aug. 27	MT
Autolus Therapeutics plc Presents Clinical Data Update at the Society of Hematologic Oncology Annual Meeting	Aug. 27	CI
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Monday Trading	Aug. 26	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Aug. 22	MT
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading	Aug. 20	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Aug. 15	MT
Syncona net asset value down 5% reflecting fall in Autolus share price	Aug. 13	AN
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	Aug. 12	MT

Truist Securities Adjusts Price Target on Autolus Therapeutics to $10 From $9, Keeps Buy Rating	Mar. 18	MT
Needham Adjusts Autolus Therapeutics Price Target to $9 From $8, Maintains Buy Rating	Feb. 12	MT
Needham Adjusts Autolus Therapeutics' Price Target to $8 From $7, Maintains Buy Rating	Jan. 22	MT
Goldman Sachs Raises Price Target on Autolus Therapeutics to $4.80 From $3.20, Maintains Neutral Rating	Dec. 13	MT
Deutsche Bank Initiates Coverage on Autolus Therapeutics With Buy Rating, $10 Price Target	Nov. 09	MT

Autolus Therapeutics plc Stock

Equities

AUTL

US05280R1005

Biotechnology & Medical Research

Valuation: Autolus Therapeutics plc

Chart: Autolus Therapeutics plc

Latest news: Autolus Therapeutics plc

Last Transcript: Autolus Therapeutics plc

Analysts' recommendations: Autolus Therapeutics plc

Press Releases: Autolus Therapeutics plc

News in other languages: Autolus Therapeutics plc

Quotes and Performance

Course Extremes

Managers and Directors: Autolus Therapeutics plc

ETFs: Autolus Therapeutics plc

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024	Aug. 27	GL
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024	Aug. 27	AQ
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates	Aug. 08	GL
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates	Aug. 08	AQ
Autolus Therapeutics : Presentation pdf	Aug. 07	PU

Biontech baut Kapazitäten durch Deal mit britischer Autolus aus	Feb. 08
WDH: Morphosys besetzt Finanzressort neu	23-03-15
Wall Street : tendance hésitante avant de nouveaux indicateurs	21-11-08
Blackstone : investissement dans Autolus Therapeutics	21-11-08

1 day	-9.80%
1 week	+1.91%
Current month	+1.91%
1 month	-0.37%
3 months	+0.12%
6 months	-25.70%
Current year	-37.81%

Director	Title	Age	Since
Martin Pulé FOU	Founder	51	14-08-31
Christian Itin CEO	Chief Executive Officer	59	14-09-30
Robert Dolski DFI	Director of Finance/CFO	54	23-08-06

Name	Weight	AuM	1st Jan change	Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	0.05%	2 M€	-.--%
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.01%	0 M€	0.00%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.01%	0 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
AUTOLUS THERAPEUTICS PLC	-9.80%	+1.91%	+28.37%	-45.51%	1.07B
REGENERON PHARMACEUTICALS, INC.	-1.66%	-4.49%	+37.11%	+69.18%	122B
VERTEX PHARMACEUTICALS INCORPORATED	-0.12%	-5.62%	+36.06%	+143.50%	121B
ARGENX SE	+0.27%	+4.17%	+1.75%	+67.91%	32.37B
BIONTECH SE	-0.23%	+1.95%	-24.88%	-74.05%	21.38B
BEIGENE, LTD.	-0.14%	-0.24%	-1.51%	-44.80%	20.33B
GENMAB A/S	-0.27%	-0.72%	-29.20%	-37.25%	17.58B
WUXI APPTEC CO., LTD.	-2.17%	-0.97%	-49.15%	-72.52%	15.54B
VAXCYTE, INC.	-0.46%	+38.16%	+123.97%	+330.81%	13.59B
SAREPTA THERAPEUTICS, INC.	-3.63%	-5.05%	+5.67%	+64.08%	12.29B
Average	-1.82%	+3.29%	+12.82%	+40.13%	37.71B
Weighted average by Cap.	-0.84%	-1.50%	+23.58%	+76.75%

	2024 *	2025 *
Net sales	15.27M	61.03M
Net income	-208M	-183M
Net Debt	-651M	-505M